A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

• Published in: Alzheimer's research & therapy 2018-05, Vol.10 (1), p.44-44, Article 44
• Main Authors: Ridha, Basil H, Crutch, Sebastian, Cutler, Dawn, Frost, Christopher, Knight, William, Barker, Suzie, Epie, Norah, Warrington, Elizabeth K, Kukkastenvehmas, Riitta, Douglas, Jane, Rossor, Martin N
• Format: Article
• Language: English
• Subjects: Aged; Alzheimer Disease - complications; Alzheimer Disease - drug therapy; Alzheimer's disease; Analysis; Atrophy - drug therapy; Atrophy - etiology; Cerebral Cortex - drug effects; Cerebral Cortex - pathology; Cholinesterase Inhibitors - therapeutic use; Clinical trial; Clinical trials; Cross-Over Studies; Donepezil; Donepezil - therapeutic use; Dosage and administration; Double-Blind Method; Drug therapy; Female; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Outcome Assessment (Health Care); Patient outcomes; Posterior cortical atrophy; Treatment Outcome
• ISSN: 1758-9193; 1758-9193
• DOI: 10.1186/s13195-018-0363-1

The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease. A single-centre, double-blind, placebo-controlled, cross-over clinical trial was performed to assess the efficacy of donepezil in patients with PCA. Each patient received either donepezil (5 mg once daily in the first 6 weeks and 10 mg once daily in the second 6 weeks) or placebo for 12 weeks. After a 2-week washout period, each patient received the other treatment arm during the following 12 weeks followed by another 2-week washout period. The primary outcome was the Mini-Mental State Examination (MMSE) at 12 weeks. Secondary outcome measures were five neuropsychological tests reflecting parieto-occipital function. Intention-to-treat analysis was used. For each outcome measure, carry-over effects were first assessed. If present, then analysis was restricted to the first 12-week period. Otherwise, the standard approach to the analysis of a 2 × 2 cross-over trial was used. Eighteen patients (13 females) were recruited (mean age 61.6 years). There was a protocol violation in one patient, who subsequently withdrew from the study due to gastrointestinal side effects. There was statistically significant (p < 0.05) evidence of a carry-over effect on MMSE. Therefore, the analysis of treatment effect on MMSE was restricted to the first 12-week period. Treatment effect at 6 weeks was statistically significant (difference = 2.5 in favour of donepezil, 95% CI 0.1 to 5.0, p < 0.05). Treatment effect at 12 weeks was close, but not statistically significant (difference = 2.0 in favour of donepezil, 95% CI -0.1 to 4.5, p > 0.05). There were no statistically significant treatment effects on any of the five neuropsychological tests, except for digit span at 12 weeks (higher by 0.5 digits in favour of placebo, 95% CI 0.1 to 0.9). Gastrointestinal side effects occurred most frequently, affecting 13/18 subjects (72%), and were the cause of study discontinuation in one subject. Nightmares and vivid dreams occurred in 8/18 subjects (44%), and were statistically more frequent during treatment with donepezil. In this small study, there was no statistically significant treatment effect of donepezil on the primary outcome measure (MMSE score at 12 weeks) in PCA patients, who appear to be particularly susceptible to the development of nightmares and vivid dreams when treated. Trial registration: Current Controlled Trials I